Vagus nerve stimulation in experimental heart failure.

Vagus nerve stimulation in experimental heart failure.
复制标题

DOI:
10.1007/s10741-010-9209-z
复制
发表时间:
2011-03
影响因子:
4.6
通讯作者:
Gupta, Ramesh C.
Gupta, Ramesh C.
中科院分区:
医学2区
文献类型:
--
作者:
Sabbah, Hani N.;Ilsar, Itamar;Zaretsky, Asaph;Rastogi, Sharad;Wang, Mengjun;Gupta, Ramesh C.

文献摘要

参考文献

被引文献

相似文献

慢性心力衰竭(HF)与自主神经功能失调有关,其特征在于交感神经驱动持续增加和副交感神经活动消退。交感神经兴奋和心率加快是心力衰竭患者长期预后不良的预测因子。有大量证据支持使用部分抑制交感神经活动的药物作为心力衰竭患者的有效长期治疗;经典的例子是选择性和非选择性β肾上腺素能受体阻滞剂的广泛使用。相比之下,由于其复杂的心血管效应,多年来,作为HF的潜在疗法的副交感神经激活的调节仅受到有限的关注。在本文中,我们回顾了最近实验动物研究的结果,这些研究为迷走神经电刺激(VNS)作为治疗慢性心力衰竭的长期疗法的可能性提供了支持。除了探讨慢性迷走神经刺激对左心室(LV)功能的影响外,该综述还将讨论迷走神经刺激对HF状态潜在修饰剂的影响,包括细胞因子的产生和一氧化氮的产生。最后,我们将简要回顾目前正在研究的其他神经刺激方法,作为治疗慢性HF的潜在治疗方式。
Chronic heart failure (HF) is associated with autonomic dysregulation characterized by a sustained increase of sympathetic drive and by withdrawal of parasympathetic activity. Sympathetic overdrive and increased heart rate are predictors of poor long-term outcome in patients with HF. Considerable evidence exists that supports the use of pharmacologic agents that partially inhibit sympathetic activity as effective long-term therapy for patients with HF; the classic example is the wide use of selective and non-selective beta-adrenergic receptor blockers. In contrast, modulation of parasympathetic activation as potential therapy for HF has received only limited attention over the years given its complex cardiovascular effects. In this article, we review results of recent experimental animal studies that provide support for the possible use of electrical Vagus nerve stimulation (VNS) as a long-term therapy for the treatment of chronic HF. In addition to exploring the effects of chronic VNS on left ventricular (LV) function, the review will also address the effects of VNS on potential modifiers of the HF state that include cytokine production and nitric oxide elaboration. Finally, we will briefly review other nerve stimulation approaches also currently under investigation as potential therapeutic modalities for treating chronic HF.
DOI: 10.1111/j.1600-0404.2006.00732.x
发表时间: 2007-01-01
影响因子: 3.5
作者:
Labiner, David M.;Ahern, Geoffrey L.
通讯作者: Ahern, Geoffrey L.
DOI: 10.1161/01.cir.0000145160.04084.ac
发表时间: 2004-10-19
期刊: CIRCULATION
影响因子: 37.8
作者:
Bendall, JK;Damy, T;Heymes, C
通讯作者: Heymes, C
DOI: 10.1172/jci200213265
发表时间: 2002-03-01
影响因子: 15.9
作者:
Mungrue, IN;Gros, R;Husain, M
通讯作者: Husain, M
DOI: 10.1111/j.1528-1157.1994.tb02482.x
发表时间: 1994-05-01
期刊: EPILEPSIA
影响因子: 5.6
作者:
BENMENACHEM, E;MANONESPAILLAT, R;WILLIS, J
通讯作者: WILLIS, J
DOI: 10.1152/ajplegacy.1968.215.5.1210
发表时间: 1968-01-01
影响因子: --
作者:
HARMAN, MA;REEVES, TJ
通讯作者: REEVES, TJ